Head-to-head · WeighScore
Lttl vs Strut Health
By GLP-1 ScorecardUpdated
Score comparison
Strut Health has the higher recorded score — 79.4/100 to 63.5/100.
Strut Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The same molecule as a lozenge or an injection at the same price — the one place here where the needle is genuinely optional.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Lttl | Strut Health |
|---|---|---|
| WeighScore | 63.5/100 | 79.4/100 |
| Grade | C | C+ |
| Site position | #210 | #28 |
| Semaglutide | $99/mo monthly auto-refill; $89/mo equivalent billed $1,068 annually (confirm supply/renewal) | From $99/mo sublingual, $149/mo injectable |
| Tirzepatide | $149/mo monthly auto-refill; $139/mo equivalent billed $1,668 annually (confirm supply/renewal) | From $199/mo either route |
| Coverage | Provider claims 50 states + DC; treatment availability varies | 49 states (not Arkansas) |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #210 · C
Strengths
- Public ordinary monthly injection rates of $99 semaglutide and $149 tirzepatide, with longer-plan charges disclosed separately
- The plan selector identifies supply lengths, including four weeks for monthly auto-refill and 52 weeks annually
- Four possible dispensing pharmacies are named in the terms, without an individual assignment established
- Microdose injection and oral-tablet selector entries provide additional options to discuss with a clinician; availability and clinical suitability require confirmation
What to consider
- Monthly, quarterly and six-month supply labels do not align with calendar-month language; confirm actual refill and debit intervals
- Medical-rejection refund language conflicts with consultation-fee retention wording
- Terms use medical intake as a nonrefund boundary, while support uses pharmacy processing/shipping; refund deadlines also differ
- The assigned treating practice, prescriber and actual dispensing location remain unestablished
- Branded-service exceptions are described, but no available brand-specific prescription or price was established
- A 48-hour shipping headline differs from the policy estimate of two to five business days processing plus three to seven in transit
Site position #28 · C+
FDAWarning letter issued to Strut Health, LLC dba Strut in February 2026. See the FDA warning-letter database.
Strengths
- Sublingual lozenges for both molecules at the same price as the injection — semaglutide from $99/mo, tirzepatide from $199/mo
- Every route and auto-refill saving published on the product page rather than inside an intake
- Free physician visit, free shipping and free follow-up care included
- Cancel, pause or delay yourself with 48 hours' notice
What to consider
- Asynchronous by design — some states need no phone consultation, so you may never speak to the prescriber
- No published lab or monitoring program
- Compounded only, with no brand-name lane
- Not available in Arkansas
Featured provider
Strut Health
Strut Health scores 79.4/100 (C+). The same molecule as a lozenge or an injection at the same price — the one place here where the needle is genuinely optional.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Strut Health, LLC dba Strut in February 2026. See the FDA warning-letter database.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.